Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.
Bourhis J, Aupérin A, Borel C, Lefebvre G, Racadot S, Geoffrois L, Sun XS, Saada E, Cirauqui B, Rutkowski T, Henry S, Modesto A, Johnson A, Chapet S, Calderon B, Sire C, Malard O, Bainaud M, Da Silva Motta A, Thureau S, Pointreau Y, Blanchard P, Buiret G, Bozec L, Lopez S, Vanbockstael J, Bosset M, Greilsamer C, Daste A, Bruna A, N'Guyen F, Plana M, Iruarrizaga E, Temam S, Even C, Ruiz EP, Bert M, Karamouza E, Thariat J, Kazmierska J, Psyrri A, Mesia R, Tao Y. Bourhis J, et al. Among authors: daste a. Lancet. 2026 Jan 24;407(10526):363-374. doi: 10.1016/S0140-6736(25)01850-1. Epub 2025 Dec 22. Lancet. 2026. PMID: 41448222 Clinical Trial.
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Rischin D, Hansen AR, Cohen EEW, Tahara M, Harrington KJ, Haddad RI, Licitra L, Mehanna H, Ferris RL, Koralewski P, Penkov K, Schenker M, Spigel DR, Daste A, Hong MH, Guo Y, Chisamore MJ, Washburn ML, Phillips-Jones A, Russell J, Roy-Ghanta S, Ellis C, Ballas M, Le Tourneau C. Rischin D, et al. Among authors: daste a. Clin Cancer Res. 2025 Dec 22. doi: 10.1158/1078-0432.CCR-25-1197. Online ahead of print. Clin Cancer Res. 2025. PMID: 41427951
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
Galot R, Le Tourneau C, Licitra L, Guigay J, Kong A, Tinhofer I, Even C, Daste A, Henry S, Borel C, Abdeddaim C, Seront E, Prevost JB, Rutten A, Saada-Bouzid E, Rolland F, Bonomo P, Rasschaert M, Dirix L, Olungu C, Tsechilidou K, Govaerts AS, Fortpied C, Joaquim A, Machiels JP. Galot R, et al. Among authors: daste a. ESMO Open. 2025 May;10(5):104554. doi: 10.1016/j.esmoop.2025.104554. Epub 2025 Apr 30. ESMO Open. 2025. PMID: 40311183 Free PMC article. Clinical Trial.
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC, Tahara M, Machiels JP, Rischin D, Seiwert TY, Ferris RL, Keilholz U, Psyrri A, Keam B, Bossi P, Metcalf R, Hsieh CY, Clement PMJ, Isaev P, Mudunov A, Dinis J, Hoeben A, Kasper S, Klinghammer K, Hwang M, Blando J, Serrano O, Ruscica D, Cohen RB; INTERLINK-1 investigators. Fayette J, et al. Clin Cancer Res. 2025 Jul 1;31(13):2617-2627. doi: 10.1158/1078-0432.CCR-25-0073. Clin Cancer Res. 2025. PMID: 40300079 Free PMC article. Clinical Trial.
Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study.
Ladouceur A, Barnetche T, Prey S, Dutriaux C, Gerard É, Pham-Ledard A, Beylot-Barry M, Zysman M, Veillon R, Domblides C, Daste A, Gross-Goupil M, Sionneau B, Lefort F, Mathieu L, Richez C, Truchetet ME, Schaeverbeke T, Kostine M. Ladouceur A, et al. Among authors: daste a. Joint Bone Spine. 2025 Jan;92(1):105795. doi: 10.1016/j.jbspin.2024.105795. Epub 2024 Oct 22. Joint Bone Spine. 2025. PMID: 39447690
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
Ladouceur A, Barnetche T, Mouterde G, Tison A, Bitoun S, Prey S, Dutriaux C, Gerard E, Pham-Ledard A, Beylot-Barry M, Zysman M, Veillon R, Domblides C, Daste A, Gross-Goupil M, Sionneau B, Lefort F, Larroquette M, Richez C, Truchetet ME, Schaeverbeke T, Kostine M. Ladouceur A, et al. Among authors: daste a. RMD Open. 2023 Nov 29;9(4):e003795. doi: 10.1136/rmdopen-2023-003795. RMD Open. 2023. PMID: 38030233 Free PMC article.
Management of 80 sinonasal undifferentiated carcinomas. Retrospective multicentre study of the French Network of Rare Head and Neck Cancers (REFCOR).
Pouvreau P, Coelho J, Rumeau C, Malard O, Garrel R, Michel J, Righini C, Vergez S, Baudouin R, Bastit V, Marie JP, Villepelet A, Moya-Plana A, Philouze P, Saroul N, Digue L, Daste A, Renard S, Moriniere S, Carsuzaa F, Verillaud B, Poissonnet G, Schultz P, Brenet E, Mouawad F, Thariat J, Vulquin N, Castain C, de Gabory L, Dupin C. Pouvreau P, et al. Among authors: daste a. Eur J Surg Oncol. 2023 Dec;49(12):107108. doi: 10.1016/j.ejso.2023.107108. Epub 2023 Oct 5. Eur J Surg Oncol. 2023. PMID: 37866154
62 results